No not at all. The reason for the amount of patients is the safety and efficacy of autologous therapies and Bioheart's safety of the protocols. This article is a biased evaluation of Mesoblast. The reason they need 1700 patients is to prove safety an efficacy since they use Allogeneic stem cells. Bioheart only needs 170. Looking at the timelines Bioheart is way ahead. The author is incorrect.
News 
Market Data 
Discover 
